Drugs for Cancer

[1]  Karol Sikora,et al.  Delivering affordable cancer care in high-income countries. , 2011, The Lancet. Oncology.

[2]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[3]  E. Felip,et al.  Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Chalkidou,et al.  Determining the value of drugs--the evolving British experience. , 2011, The New England journal of medicine.

[5]  M. Stratton.  Exploring the Genomes of Cancer Cells: Progress and Promise , 2011, Science.

[6]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[7]  R. Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[8]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[9]  M. Rawlins.  A new era for UK clinical research? , 2011, The Lancet.

[10]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[11]  M. Ratain.  Bar the windows but open the door to randomization. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[13]  Timothy R. Coté,et al.  Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years , 2010, Nature Reviews Drug Discovery.

[14]  J. Spicer,et al.  EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992 , 2010, Targeted Oncology.

[15]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[16]  P. Bruzzi,et al.  Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. O'Doherty,et al.  Molecular imaging in clinical trials , 2009, Targeted Oncology.

[18]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[19]  S. Bates,et al.  Epigenetic Modifiers: Basic Understanding and Clinical Development , 2009, Clinical Cancer Research.

[20]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[21]  M. Christian,et al.  Novel Designs and End Points for Phase II Clinical Trials , 2009, Clinical Cancer Research.

[22]  N. Spector,et al.  Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors , 2008, Clinical Cancer Research.

[23]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[24]  Alasdair Breckenridge,et al.  Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma , 2008, Nature Reviews Drug Discovery.

[25]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[26]  C. Croce.  Oncogenes and cancer. , 2008, The New England journal of medicine.

[27]  Kathryn L Chapman,et al.  Preclinical safety testing of monoclonal antibodies: the significance of species relevance , 2007, Nature Reviews Drug Discovery.

[28]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[29]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[30]  A. Adjei.  What is the right dose? The elusive optimal biologic dose in phase I clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[33]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[34]  B. Coiffier,et al.  State-of-the-art therapeutics: diffuse large B-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Hoff,et al.  Angiogenesis inhibitors in the treatment of cancer , 2005, Expert opinion on pharmacotherapy.

[36]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[37]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[38]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[39]  G. Sledge,et al.  What is targeted therapy? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Seiichiro Yamamoto,et al.  Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.

[41]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[43]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Choueiri,et al.  Role of aromatase inhibitors in the treatment of breast cancer. , 2004, Clinical therapeutics.

[45]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.

[46]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[47]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[48]  J. Baselga.  Why the epidermal growth factor receptor? The rationale for cancer therapy. , 2002, The oncologist.

[49]  M. Roach,et al.  Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. , 2002, Seminars in oncology.

[50]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[51]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[52]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[53]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[55]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[56]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[57]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[58]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[59]  A. Gilman,et al.  The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. , 1946, Science.

[60]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[61]  I. Tannock,et al.  Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Piantadosi,et al.  Practical implementation of a modified continual reassessment method for dose-finding trials , 1998, Cancer Chemotherapy and Pharmacology.